Brokerages Set Affimed (NASDAQ:AFMD) Price Target at $13.50

Affimed (NASDAQ:AFMD) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $13.50.

A number of analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research note on Tuesday, December 10th. Stifel Nicolaus decreased their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. Wells Fargo & Company cut their price target on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Tuesday, November 19th.

Affimed Stock Performance

Shares of NASDAQ AFMD opened at $1.19 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a 1-year low of $1.14 and a 1-year high of $8.95. The business has a 50-day moving average of $2.88 and a 200-day moving average of $3.98.

Institutional Investors Weigh In On Affimed

A number of institutional investors have recently made changes to their positions in the company. FMR LLC boosted its holdings in Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares during the period. Choreo LLC acquired a new position in shares of Affimed in the 2nd quarter valued at about $54,000. Intellectus Partners LLC grew its position in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the last quarter. Jane Street Group LLC acquired a new stake in Affimed during the third quarter worth about $44,000. Finally, Point72 Asset Management L.P. boosted its stake in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the period. 30.82% of the stock is currently owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.